Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283

,; Turck, Dominique; Bohn, Torsten; Castenmiller, Jacqueline; De Henauw, Stefaan; Hirsch‐Ernst, Karen Ildico; Maciuk, Alexandre; Mangelsdorf, Inge; McArdle, Harry J; Naska, Androniki; Pentieva, Kristina; Siani, Alfonso; Thies, Frank; Tsabouri, Sophia; Vinceti, Marco; Aguilera‐Gómez, Margarita; Cubadda, Francesco; Frenzel, Thomas; Heinonen, Marina; Prieto Maradona, Miguel; Marchelli, Rosangela; Neuhäuser‐Berthold, Monika; Peláez, Carmen; Poulsen, Morten; Schlatter, Josef Rudolf; Siskos, Alexandros; van Loveren, Henk; Colombo, Paolo; Noriega Fernández, Estefanía; Knutsen, Helle Katrine

doi:10.2903/j.efsa.2023.8333

EFS2

2023

DOI: 10.2903/j.efsa.2023.8333

|View full text |Cite

Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283

Dominique Turck,

Torsten Bohn,

Jacqueline Castenmiller

et al.

Abstract: Safety of 2 0 -fucosyllactose (2'-FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476)

Food Standards Agency,

Food Standards Scotland

2024

FSA Research and Evidence

View full text Add to dashboard Cite

The Food Standards Agency (FSA) and Food Standards Scotland (FSS) received an application from Kyowa Hakko Bio Company Ltd, Japan (“the applicant”) for the authorisation of 2’-fucosyllactose (2’-FL) as a novel food in March 2022. The novel food is intended to be used as a source of human identical milk oligosaccharide, 2’-FL, and is manufactured by microbial fermentation using a genetically modified strain of Escherichia coli W, and then refined to yield the purified powder. This new application is seeking to use the novel food within the following food categories: dairy products and analogues, bakery wares, table-top sweeteners, foods for special groups, beverages, and food supplements. Food supplements are not intended to be used if other foods with added 2’-FL or breast milk are consumed the same day. The intended uses and use levels for the novel food are the same as those that have already been authorised for 2’-FL produced by fermentation with genetically modified strains of E. coli BL21 (DE3), E. coli K-12 DH1, and Corynebacterium glutamicum ATCC 13032. However, this application is also seeking to use 2’-FL as a food supplement for infants, which is not currently authorised. To support the FSA and FSS in their evaluation of the application, the Advisory Committee on Novel Foods and Processes (ACNFP) were asked to review the safety dossier and supplementary information provided by the applicant. The views of the Committee were taken into account by the FSA and FSS who concluded that the applicant had provided sufficient information to assure the novel food, 2-FL, was safe under the proposed conditions of use. The anticipated intake levels and the intended use in food and food supplements was not considered to be nutritionally disadvantageous. This safety assessment represents the opinion of the FSA and FSS.

show abstract

Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476)

Food Standards Agency,

Food Standards Scotland

2024

FSA Research and Evidence

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283

Abstract: Safety of 2 0 -fucosyllactose (2'-FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),

Cited by 1 publication

References 21 publications

Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476)

Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476)

Contact Info

Product

Resources

About